January 30, 2003
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Allergan net sales increase, profit falls
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
IRVINE, Calif. — Allergan Inc. earnings from continuing operations rose 21% for the year, led by pharmaceutical sales increases of around 8.3%, according to a company statement. Net sales for the company for the year increased 19.9% to $1.4 billion.
However, net profit fell to $64.4 million from $84 million during fiscal 2001, the statement said.
Net sales for the fourth quarter rose to $378.2 million, attributable mainly to increased sales of glaucoma medications and Botox, according to the company.
Sales of glaucoma products for fiscal 2002 increased 24.6% from 2001. Sales of the Alphagan (brimonidine) product line were $248.5 million. Sales of Lumigan (bimatoprost) increased 245.8% to $123 million.